Development of Software for Finger Joint Space Narrowing Progression for Rheumatoid Arthritis Patients on Drug Therapy

Development of Quantitative Software for Joint Space Narrowing Progression on Radiography for Rheumatoid Arthritis Patients on Tocilizumab - Development of Quantitative Software for Joint Space Narrowing Progression

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000040772

Enrollment

Registered

2020-06-22

Start date

2020-07-31

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Those who have a confirmed diagnosis of rheumatoid arthritis based on the 2010 standard 2.Those who have completed one year of Tocilizumab treatment 3. Radiography of the hands at the start of treatment and at 24 and 52 weeks after the start of treatment 4. Those who do not refuse to participate in this research

Exclusion criteria

Exclusion criteria: 1.Those with severe joint destruction-Steinbrocker Stage III (high altitude progression) or higher 2. In addition, the person who the research director judges to be inappropriate as a research target person

Design outcomes

Primary

Measure	Time frame
To prove correlation in joint space narrowing progression between our proposed system and standard system from baseline to week 52.	—

Secondary

Measure	Time frame
To prove that our proposed system can show joint space narrowing (JSN) progression at week 52 is grater in those with greater JSN progression at week 24. To show correlation in JSN progression between at week 52 and at week 24 using our proposed system. To show JSN progression at week 52 is greater than that at week 24 using our proposed system. To prove the group with higher disease activity at week 0 has significantly greater JSN than that with lower disease activity at followup.	—

Measure

Time frame

To prove that our proposed system can show joint space narrowing (JSN) progression at week 52 is grater in those with greater JSN progression at week 24. To show correlation in JSN progression between at week 52 and at week 24 using our proposed system. To show JSN progression at week 52 is greater than that at week 24 using our proposed system. To prove the group with higher disease activity at week 0 has significantly greater JSN than that with lower disease activity at followup.

—

Countries

Japan

Contacts

Public ContactTamotsu Kamishima

Faculty of Health Sciences, Hokkaido University Dept. of Biomedical Science and Engineering

ktamotamo2@hs.hokudai.ac.jp+81117062824

Outcome results